Core Insights - Aquiline Drones Corporation has partnered with Ryder System, Inc. and Vets to Drones to launch a discounted drone franchise program exclusively for U.S. Veterans, providing a lifelong opportunity beyond 2025 [1][2] - The program offers a 30% discount on drone franchises for qualified Veterans, with Ryder providing substantial discounts on franchise vehicles and Vets to Drones offering free professional drone training [2] Company Initiatives - Aquiline Drones recognizes the efforts of the Small Business Administration (SBA) and its VetsCert program, which empowers Service-Disabled Veteran-Owned Small Businesses (SDVOSBs) to compete for specialized contracts, particularly within the Department of Veteran Affairs [3] - The partnership aims to advance federal initiatives like the U.S. Department of War's Blue UAS program and the Replicator Initiative, focusing on expanding secure, American-made drone systems [5][6] Veteran Empowerment - The initiative seeks to enhance Veteran involvement in national security and industry growth by fostering entrepreneurship and enabling military veterans to transition into small-business ownership roles [8][9] - Aquiline Drones' franchise model includes structured training, business development support, and access to federal contracting opportunities for Veteran-owned businesses [7] Market Potential - The U.S. drone market is projected to exceed $60 billion in the next decade, driven by defense upgrades, infrastructure monitoring, and commercial drone adoption [9][10] - The franchise initiative is designed for rapid expansion across multiple states through collaborations with Veterans' organizations and government entities, ensuring franchisees are prepared for civilian and defense contracts [9][10] Strategic Goals - The partnership aims to bolster local economies and advance U.S. technological leadership by creating a robust ecosystem that empowers Veterans with resources and solutions [11][13] - The initiative aligns with national directives to strengthen the domestic UAS industrial base and promote Veteran-owned federal contracting goals [13][14]

Core Points - NuGen Medical Devices has announced that its EziAutoJector® product line has received NHS Drug Tariff approval in the UK, allowing diabetes patients to access the device at no cost as part of NHS-funded care [1][2][6] - The approval aligns with NICE guidelines, promoting personalized patient choice in insulin delivery methods, and ensures pharmacists are reimbursed for dispensing the product [2][6] - EziAutoJector® Ltd has established distribution channels through a major pharmaceutical wholesaler, targeting both high-street pharmacies and online pharmacy services [3] - A direct-to-consumer e-commerce channel will enhance accessibility for patients facing prescribing restrictions [4] - Transitioning to EziAutoJector® allows patients to eliminate the use of over 1,000 single-use insulin needles annually, reducing biohazardous waste and supporting NHS environmental goals [5][6] Company Overview - NuGen Medical Devices specializes in needle-free drug delivery technology, with its flagship InsuJet™ system approved in 42 countries [6]

Core Insights - Ryder System, Inc. has consistently rewarded shareholders through dividends and share buybacks, with a total return of $456 million in 2024 and $71 million in dividends along with $261 million in share repurchases in the first half of 2025 [1][10] Dividend Policy - On July 10, 2025, Ryder's board approved a 12% increase in its quarterly cash dividend, raising it to 91 cents per share from 81 cents, reflecting the company's commitment to enhancing shareholder returns [2][5] - This dividend hike is the first since July 2024, marking Ryder's 196th consecutive quarterly cash dividend and demonstrating over 49 years of uninterrupted dividend payments [3][10] Market Position and Performance - Ryder's stock has shown strong performance, improving in double digits over the past year and outperforming the Zacks Transportation - Equipment and Leasing industry [9] - The stock is currently trading at a forward 12-month price-to-sales ratio of 0.57X, significantly lower than the industry average of 1.94X, indicating an attractive valuation [13] Industry Context - Other companies in the transportation sector, such as Kirby Corporation and Werner Enterprises, have also engaged in share buyback programs in 2025, reflecting a broader trend of returning capital to shareholders [6][7] - Union Pacific Corporation has similarly increased its dividend by 3%, showcasing a commitment to shareholder returns within the industry [8]

Core Viewpoint - Theralase Technologies Inc. has announced the peer-reviewed publication of preclinical data demonstrating that its antiviral candidate Ruvidar® is more effective than Acyclovir® and Metformin® in treating Herpes Simplex Virus Type 1 (HSV-1) [1][2][3] Company Summary - Theralase Technologies Inc. is a clinical stage pharmaceutical company focused on developing light, radiation, sound, and drug-activated therapeutics for treating various diseases, including cancer and viral infections [1][8] - The company is advancing Ruvidar® into clinical development, with plans for a Phase I/II adaptive clinical study in 2026 to assess its safety and efficacy in treating cold sore lesions [1][6] Research Findings - The latest research published in MDPI - Viruses indicates that Ruvidar® significantly inhibits HSV-1 replication post-infection, unlike Acyclovir® and Metformin®, which show little effect once infection is established [2][3] - Ruvidar® has demonstrated effectiveness against Acyclovir®-resistant HSV-1 mutants, highlighting its potential as a next-generation antiviral therapy [3][4] - The combination of Ruvidar® with Acyclovir® proved to be more effective than either treatment alone, suggesting potential for combinational therapies [4][6] Market Context - The global HSV treatment market was estimated at $2.8 billion in 2024 and is projected to grow to $4.7 billion by 2033, indicating a significant opportunity for effective antiviral treatments like Ruvidar® [8]

Core Viewpoint - Zomedica Corp. has expanded its TRUFORMA diagnostic platform to include feline testing capabilities for its cobalamin and folate assay, marking a significant advancement in veterinary diagnostics [1] Group 1: Product Development - The TRUFORMA diagnostic platform now offers a multiplexed assay that combines cobalamin and folate testing, which was previously available only for canine patients [1] - This assay is the first of its kind to provide both cobalamin and folate testing in an in-clinic setting, enhancing the diagnostic capabilities for veterinarians [1] Group 2: Market Position - Zomedica is positioned as an innovative veterinary health company focused on point-of-care diagnostic and therapeutic device products for both equine and companion animals [1]

Core Viewpoint - The Zacks Transportation - Equipment and Leasing industry is facing a challenging macroeconomic environment characterized by persistent inflation, tariff-related tensions, and supply-chain disruptions, alongside geopolitical issues [1][5]. Industry Overview - The industry encompasses companies that provide equipment financing, leasing, and supply-chain management services, including aircraft, railcar, and intermodal container lessors. It also includes logistics and transportation solutions for a diverse customer base, primarily in automotive, electronics, transportation, grocery, lumber, food service, and home furnishing sectors [3]. Financial Performance and Shareholder Returns - Companies like Wabtec Corporation and Ryder System are noted for their shareholder-friendly initiatives, such as dividend payouts and share buybacks, indicating strong financial health. Ryder recently approved a 12% dividend increase, raising its quarterly cash dividend to 91 cents per share, while Wabtec announced a 25% increase, raising its quarterly cash dividend from 20 cents to 25 cents [2][4]. Economic Challenges - The industry is grappling with ongoing tariff tensions and inflation, which contribute to economic uncertainty and may hinder stock performance. Supply-chain disruptions and rising operating costs are also limiting growth potential [5][6]. Industry Ranking and Performance - The Zacks Transportation - Equipment and Leasing industry holds a Zacks Industry Rank of 75, placing it in the top 31% of over 250 Zacks industries. However, it has underperformed compared to the S&P 500 and the broader sector over the past year, declining 18.4% against the S&P 500's increase of 18.7% [7][9][10]. Current Valuation - The industry is currently trading at a forward 12-month price-to-earnings (P/E) ratio of 13.99X, which is lower than the S&P 500's 23.52X and the sector's 13.84X. Historically, the industry has traded between 8.42X and 15.65X over the past five years [13]. Notable Companies to Watch - **Wabtec Corporation**: Focused on technology-based locomotives and services, Wabtec has shown strong earnings performance, with a 17.6% expected earnings growth rate for 2025 [17][19]. - **Ryder System**: A logistics and transportation company with a long history of dividend payments, Ryder has an expected earnings growth rate of 9.3% for 2025 [22][23]. - **The Greenbrier Companies**: Specializing in railroad freight car equipment, Greenbrier has a notable earnings surprise history and an expected earnings growth rate of 33.1% for 2025 [26][28].

MARKHAM, ON / ACCESS Newswire / September 22, 2025 / iFabric Corp. ("iFabric" or the "Company") (TSX:IFA)(OTCQX:IFABF) today announced that its wholly owned subsidiary, Intelligent Fabric Technologies (North America) Inc. ("IFTNA"), has renewed its license agreement with TUMI, Inc. ("TUMI") to continue integrating IFTNA's PROTX2® antimicrobial solutions across select TUMI products. The renewal extends the relationship first announced on May 5, 2021, by a further period of five years. ...

Inverite Achieves Milestone SOC 2(R) Type II Audit Validation and Data Security ControlsSeptember 18, 2025 8:00 AM EDT | Source: Inverite Insights Inc.Vancouver, British Columbia--(Newsfile Corp. - September 18, 2025) - Inverite Insights Inc. (CSE: INVR) (OTC Pink: INVRD) (FSE: 2V0) ("Inverite") is a leading AI-driven software provider utilizing real-time financial data to empower businesses to transact more effectively with consumers, today announced it has successfully completed its SOC 2® T ...

Core Insights - Zomedica Corp. has strengthened its intellectual property portfolio with the issuance of four additional U.S. patents for its TRUVIEW and TRUFORMA diagnostic platforms [1] - The veterinary diagnostics market is currently valued between $8 billion and $11 billion and is projected to grow to $17 billion to $22 billion by 2030-2032, with a compound annual growth rate (CAGR) of 9-11% [1] Company Summary - Zomedica now holds a total of 228 patents and 153 trademarks, providing robust protection for its product platforms [1] - The company focuses on innovative point-of-care diagnostic and therapeutic device products for equine and companion animals [1]

Core Viewpoint - enVVeno Medical Corporation is seeking to appeal the not-approvable letter from the FDA regarding its VenoValve® device for treating severe deep chronic venous insufficiency [1] Group 1: Company Actions - The company plans to file a request for a supervisory appeal to challenge the FDA's decision received on August 19, 2025 [1] - The appeal will utilize the FDA's internal mechanisms to contest the review staff's decision, which may involve scientific controversies [1] Group 2: Product Information - The VenoValve® is a surgical replacement venous valve designed for the treatment of severe deep chronic venous insufficiency (CVI) [1]